Posts by Douglas M. Dahl, MD
-
Less Aggressive Protocol Suitable for Muscle-invasive Bladder Cancer in Noncystectomy Candidates
Douglas M. Dahl, MD, Jason A. Efstathiou, MD, DPhil, and colleagues determined that in patients with muscle-invasive bladder cancer who were not candidates for cystectomy or cisplatin, maximum tumor resection and chemoradiation were associated with high response rates and five-year overall survival rates of 25% to 38%.
-
Combined Standard and Targeted Transperineal Biopsies Advised for Patients With Prostate Lesion on Multiparametric MRI
Massachusetts General Hospital researchers recommend patients who have a prostate lesion on multiparametric MRI should undergo both standard and targeted biopsy using the transperineal approach, as that resulted in a Gleason grade most concordant with the results from radical prostatectomy specimens.
-
Genetic Signature Predicts Metastasis, Survival in Clear Cell Renal Cell Carcinoma
Shenglin Mei, PhD, Philip J. Saylor, MD, David B. Sykes, MD, PhD, and colleagues found that simultaneous expression of four specific genes predicts survival and metastasis in human clear cell renal cell carcinoma, and they identified other potential therapeutic targets.
-
Targeted Biopsy Alone Detects Clinically Significant Cancer in Smaller Prostates
Douglas M. Dahl, MD, Chin-Lee Wu, MD, PhD, and colleagues found that in patients with smaller prostates (≤30 mL), transperineal multiparametric MRI-targeted biopsy alone does as well as the combination of targeted and conventional biopsy at detecting clinically significant cancer.
-
MRI–Ultrasound Fusion–Targeted Transperineal Prostate Biopsy Complements Standard Biopsy for Detecting Perineural Invasion
Chin-Lee Wu, MD, PhD and Douglas M. Dahl, MD, of the Department of Urology, and colleagues detected perineural invasion in 32% of men with suspicious prostate lesions by combining transperineal MRI–ultrasound fusion–targeted prostate biopsy with standard 20-core template transrectal biopsy.
-
Transperineal Prostate Biopsy Feasible in Outpatient Practice
Douglas M. Dahl, MD, and colleagues reviewed their initial experience with in-office transperineal prostate biopsy. After 130 procedures, they noted no infectious complications and an antibiotic utilization rate of 48%.
-
Prostate Cancer and Translational Research
Douglas Middleton Dahl, MD, is chief of the Division of Urologic Oncology at Massachusetts General Hospital, as well as director of Robotic Surgery. In this video, he discusses his translational research on prostate cancer cells and explains how this work will advance patient care.
-
Robotic Surgery: Advances in Minimally Invasive Surgery
Douglas Middleton Dahl, MD, is chief of the Division of Urologic Oncology and clinical co-director of the Claire and John Bertucci Center for Genitourinary Cancers at Mass General Cancer Center, as well as director of Robotic Surgery and a urologic surgeon in the Department of Urology at Massachusetts General Hospital. In this video, he explores the evolution of urologic surgery and highlights opportunities made available through advances in minimally invasive techniques.
-
Transperineal Fusion Prostate Biopsy Increases Diagnostic Accuracy
Massachusetts General Hospital physicians have developed an office-based transperineal fusion prostate biopsy for accurate, safe prostate cancer diagnosis.
-
Ultrasound Therapy Yields Promising Results for Localized Prostate Cancer
At the American Urological Association's 2019 Annual Meeting, researchers presented the findings of a study on the effects transurethral ultrasound ablation (TULSA), a novel minimally invasive procedure that can reduce prostate size and prostate-specific antigens in patients with localized prostate cancer.
-
AUA 2019: A Media Roundup
At the 2019 AUA Annual Conference, urologists from Mass General discussed research findings, novel treatment approaches and advances in clinical care, including...
-
Five Sessions to See at #AUA2019
The American Urological Association (AUA) is hosting its Annual Meeting in Chicago, IL from May 3-6, 2019. Specialists from the Massachusetts General Hospital Department of Urology will present on leading research and innovative treatment approaches. Mass General doctors will participate in over 20 different sessions covering the full spectrum of urologic care, including bladder, prostate, urologic oncology and more.
-
Noninvasive Assay Predicts Drug Response, Early Dissemination in Prostate Cancer
Researchers at Massachusetts General Hospital have developed a digital assay that quantifies prostate tumor cells in blood samples, and the results predict response to the drug abiraterone in metastatic cancer or early dissemination of localized disease.
-
Advantages of Robot-assisted Techniques for Urologic Surgeries
Robotic surgery can decrease blood loss and patient pain, lead to a shorter recovery time than a traditional laparoscopic approach, and offers surgeons a shorter learning curve.
-
Early Radiotherapy Best When Cancer Recurs After Radical Prostatectomy
The optimal timing of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy is controversial. Mass General researchers aim to clear up the controversy by reviewing patients who were treated in the modern era of PSA testing.
-
Modified Paclitaxel Plus Daily Radiation Helps Noncystectomy Candidates
Physicians at Massachusetts General Hospital are in the early stages of testing a novel regimen for patients with muscle-invasive urothelial bladder cancer who are medically unfit for radical cystectomy or platinum-based radiosensitizing chemotherapy.
Biography
Dr. Dahl graduated from Princeton University with honors where he majored in molecular biology. His thesis project was to study genes related to the development of cancer. He then attended medical school at Yale University, where he graduated in the top 10% of his class as recognized by the AOA honor medical society. His internship and residency training were at Harvard. He spent two years in general surgery training at the Brigham and Women's hospital, Boston Children's hospital, and West Roxbury V.A. Hospital. He then completed four years of training in Urology in the Harvard Longwood Area program in Urology. This program included training at the above-mentioned hospitals and the Beth Israel Hospital of Boston. He served as a research fellow at the Dana Farber Cancer Institute, where he studied the genetics of prostate cancer. He then moved to the University of Massachusetts Medical Center, where he was the head of urologic laparoscopic surgery. It was there that many firsts in New England took place: The first laparoscopic kidney donor surgery for transplant, and the first laparoscopic radical prostatectomy surgery.
In 2001, he was recruited to start the program in laparoscopic and minimally invasive surgery at Massachusetts General Hospital. His contributions have been recognized by the hospital, where he serves as Director of Robotic Surgery and Chief of the Division of Urologic Oncology. He has also been honored by Harvard Medical School with the title of Associate Professor of Surgery.
Subscribe to the latest updates from Urology Advances in Motion